Comparison of the clinical efficacy of donafinil and lenvatinib in the treatment of intermediate and advanced hepatocellular carcinoma.

He, Qinzhen; Guo, Mengguang; Ya, Yanhong; Huang, Jinli; Liu, Aiqiu; Jing, Wexiang

He, Qinzhen; Guo, Mengguang; Ya, Yanhong; Huang, Jinli; Liu, Aiqiu; Jing, Wexiang.

Afiliação

He Q; Oncology Department, No. 1 People's Hospital of Hechi Hechi 546300, Guangxi, China.
Guo M; Oncology Department, No. 1 People's Hospital of Hechi Hechi 546300, Guangxi, China.
Ya Y; Oncology Department, No. 1 People's Hospital of Hechi Hechi 546300, Guangxi, China.
Huang J; Oncology Department, No. 1 People's Hospital of Hechi Hechi 546300, Guangxi, China.
Liu A; Oncology Department, No. 1 People's Hospital of Hechi Hechi 546300, Guangxi, China.
Jing W; Surgery Department, No. 1 People's Hospital of Hechi Hechi 546300, Guangxi, China.

Am J Transl Res ; 15(5): 3579-3585, 2023.

Article em En | MEDLINE | ID: mdl-37303659

Palavras-chave

Hepatocellular carcinoma; donafenil; lenvatinib

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Am J Transl Res Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google